Determination of Serum/Plasma Concentrations of Psychotropic Drugs in Therapeutic Drug Monitoring
https://doi.org/10.37489/2587-7836-2021-1-3-13
Abstract
The article considers the main methodological methods of therapeutic drug monitoring (TDM) of psychotropic drugs. Analytical methods that allow performing these studies have been described. It has been given the interpretation, examples and brief results of two studies of TDM of antipsychotic drugs made in FSBSI “Mental Health Research Center” and Psychiatric hospital No.14 in Moscow.
About the Authors
I. I. Miroshnichenko
FSBSI «Mental Health Research Center»
Russian Federation
Russian Federation
Miroshnichenko Igor I., Dr. Sci. (Med.), Head of pharmacokinetics laboratory
SPIN code: 4117-9703
Moscow
N. V. Baymeeva
FSBSI «Mental Health Research Center»
Russian Federation
Russian Federation
Baymeeva Nalalia V., Researcher of pharmacokinetics laboratory
SPIN code: 7080-2142
Moscow
A. I. Platova
FSBSI «Mental Health Research Center»
Russian Federation
Russian Federation
Platova Angelina I., Researcher of pharmacokinetics laboratory
SPIN code: 6656-2194
Moscow
References
1. Buclin T, Thoma Y, Widmer N, Pascal A, Monia G, Chantal C, Laurent A. Decosterd. The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated with Imatinib. Front Pharmacol. 2020; 11:177. DOI: 10.3389/fphar.2020.00177.
2. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1-02):9–62. DOI: 10.1055/s-0043-116492.
3. Jönsson AK, Spigset O, Reis MA. Compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting. Ther Drug Monit. 2019;41(3):348–356. DOI: 10.1097/FTD.0000000000000585.
4. Wyska E. Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert Opinion on Drug Metabolism & Toxicology. 2019;15(10):831–847. DOI: 10.1080/17425255.2019.1669560.
5. Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R. Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment. Pharmacol Ther. 2020 Nov; 215:107627. DOI: 10.1016/j.pharmthera.2020.107627.
6. Legare N, Gregoire CA, De Benedicts L, Dumais A. Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. Med Hypotheses. 2013;80(6):689–691. DOI: 10.1016/j.mehy.2012.12.024.
7. Sutherland JJ, Morrison RD, Daniels JS, Milne SB, Ryan TP. Managing psychotropic medications in complex, real-world patients using comprehensive therapeutic drug monitoring. ACS Chem. Neurosci. 2017; 8: 1641–1644. DOI: 10.1021/acschemneuro.7b00209.
8. Мирошниченко ИИ. Рациональное дозирование и мониторинг лекарственных средств. – М.: Медицинское информационное агентство. 2011. 416 c. [Miroshnichenko II. Racional'noe dozirovanie i monitoring lekarstvennyh sredstv. Moscow: Medicinskoe informacionnoe agentstvo. 2011. (In Russ).].
9. Ooba N, Tsutsumi D, Kobayashi N, Hidaka S, Hayashi H, Obara T, Satoh M, Kubota K, Fukuoka N. Prevalence of therapeutic drug monitoring for lithium and the impact of regulatory warnings: analysis using japanese claims database. Ther Drug Monit. 2018;40(2):252–256. DOI: 10.1097/FTD.0000000000000483.
10. Gervasini G., Benítez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol. 2010;66(8):755–774. DOI: 10.1007/s00228-010-0857-7.
11. Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmäder K, Härtter S, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, Rollmann N, Weigmann H, Weber-Labonte M, Hiemke C. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry. 2003;36(3):98–104. DOI: 10.1055/s-2003-39983.
12. Brandhorst G, Oellerich M, Maine G, Taylor P, Veen G, Wallemacq P. Liquid chromatography–tandem mass spectrometry or automated immunoassays: what are the future trends in therapeutic drug monitoring? Clin Chem. 2012;58(5):821–825. DOI: 10.1373/clinchem.2011.167189.
13. Tuzimski T, Petruczynik A. Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM). Molecules. 2020;25(17):4026. DOI: 10.3390/molecules25174026.
14. Miroshnichenko II., Baymeeva NV. Simultaneous determination of antipsychotic drugs and their active metabolites by LC-MS-MS and its application to therapeutic drug monitoring. J Chromatogr Sci. 2018;56(6): 510–517. DOI: 10.1093/chromsci/bmy024.
15. Srinivas NR. Should commonly prescribed drugs be avoided as internal standard choices in new assays for clinical samples? Bioanalysis. 2016; 8(7):607–610. DOI: 10.4155/bio.16.21
16. Fuchs A, Chantal C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013;52(1):9–22. DOI: 10.1007/s40262-012-0020-y.
Review
For citations:
Miroshnichenko I.I., Baymeeva N.V., Platova A.I. Determination of Serum/Plasma Concentrations of Psychotropic Drugs in Therapeutic Drug Monitoring. Pharmacokinetics and Pharmacodynamics. 2021;(1):3-13. (In Russ.) https://doi.org/10.37489/2587-7836-2021-1-3-13
Views:
569
Email this article 